Introduction to
FFPE Samples with DNA Sequencing Data
Buy FFPE Samples With DNA Sequencing Data
FFPE samples with DNA sequencing data provide researchers with preserved human tissue accompanied by information about identified genomic alterations. Depending on the testing method, the data may include single-nucleotide variants, insertions, deletions, copy-number alterations and other clinically or scientifically relevant findings. These samples can support oncology research, molecular assay development, biomarker validation, drug discovery and precision-medicine studies. Researchers may obtain FFPE blocks, tissue sections, curls or extracted nucleic acids, subject to tissue availability and project requirements. Before purchasing, it is important to review the sequencing platform, gene-panel coverage, quality metrics, tumour percentage and interpretation of reported variants.
Pathologist-reviewed H&E slides can confirm diagnosis and determine whether sufficient representative tumour remains for further testing. Clinical annotations, including cancer type, stage, grade and treatment history, may also be available. Ethically sourced FFPE samples with reliable sequencing data can reduce prescreening requirements and help researchers assemble molecularly defined cohorts more efficiently.
FFPE Samples With DNA Sequencing for Oncology Research
FFPE samples with DNA sequencing results can help oncology researchers examine the genetic alterations associated with tumour development, progression and potential treatment response. The tissue may be selected according to cancer indication, histological subtype, mutation status or a specific molecular pathway. Existing sequencing findings can be compared with newly generated results from IHC, FISH, PCR, RNA sequencing, spatial biology or additional DNA-based assays
Optimized for DNA Sequencing
NGS-Ready FFPE Tissue Blocks
Reliable RNA Profiling Samples
Clinically Annotated FFPE Samples With DNA Sequencing
Clinically annotated FFPE samples with DNA sequencing combine molecular findings with pathological and patient-level information. Available annotations may include age, sex, diagnosis, tumour site, histological subtype, stage, grade, treatment exposure, response and follow-up. This integrated information can support retrospective studies examining associations between genomic alterations and clinical characteristics. However, annotation depth varies among cohorts, and researchers should define mandatory data fields before sample selection begins.
Clinically Annotated Tissue Samples
FFPE blocks supplied with relevant clinical details for reliable genomic research.
Comprehensive Pathology Data Included
Each sample includes diagnosis, grade, stage, tumor content, and pathology information.
Optimized for Genomic Analysis
Samples are suitable for DNA, RNA, NGS, mutation analysis, and molecular profiling.
Reliable Samples for NGS
Quality-controlled FFPE blocks support accurate sequencing and reproducible genomic results.
Source FFPE Tumor Samples With Validated Sequencing Results
FFPE tumour samples with validated sequencing results can be sourced according to specific molecular and pathological criteria. Researchers may request samples carrying confirmed mutations, gene amplifications, deletions or other genomic alterations relevant to their study. Validation may involve repeat sequencing, confirmation through an orthogonal method or review of an existing laboratory report. The appropriate validation standard should be defined before procurement because research-grade and clinical-grade sequencing reports may differ in scope and documentation.
Â
Researchers should specify the acceptable sequencing platform, gene-panel coverage, minimum variant allele frequency, tumour percentage and required tissue quantity. A recent H&E section can help confirm tissue quality, diagnosis and tumour content. The sample manifest may also include stage, grade, primary or metastatic status and available clinical information. When necessary, additional services such as macrodissection, DNA extraction or confirmatory PCR can be arranged. A controlled sourcing process helps minimise unsuitable specimens and enables researchers to build reliable mutation-positive and mutation-negative study cohorts.
FFPE Samples With DNA Sequencing for Biomarker Studies
FFPE samples with DNA sequencing data are useful for biomarker studies that investigate connections between genomic alterations and measurable tissue characteristics. Researchers can analyse the samples using IHC, multiplex IHC, FISH, PCR, digital pathology or spatial technologies and compare the findings with existing DNA results. This approach can support biomarker discovery, assay optimisation and preliminary analytical validation. Samples may be selected according to specific mutations, alteration classes, cancer types or molecular signatures.
The reliability of the study depends on the quality of both the tissue and sequencing information. Researchers should therefore review tumour percentage, necrosis, fixation conditions, DNA quality, sequencing coverage and variant interpretation. Suitable negative controls should have adequate coverage of the gene and alteration being studied rather than simply lacking a reported mutation. Clinical annotations can further strengthen the cohort when they are complete and consistently defined. Carefully selected FFPE samples with DNA sequencing data can reduce screening costs and accelerate tissue-based biomarker research.
Order Molecularly Characterized FFPE Samples for Research
Molecularly characterized FFPE samples can be ordered using customised inclusion and exclusion criteria. A research request should specify the required tumour type, histological subtype, stage, specimen format, biomarker status and genomic alteration. Researchers should also define minimum tumour content, maximum necrosis, acceptable block age and remaining tissue requirements. Available molecular characterization may include targeted DNA sequencing, WES, WGS, PCR, FISH, IHC or comprehensive genomic profiling. A preliminary manifest can be reviewed to confirm sample eligibility before procurement. Supporting documentation may include a pathology summary, H&E image, de-identified sequencing report, testing methodology and available clinical annotations. Additional preparation services can include unstained slide sectioning, tissue curls, macrodissection or nucleic-acid extraction. All samples should be collected, processed and transferred under appropriate informed consent, ethical approval and material-transfer terms. Custom ordering allows biotechnology, pharmaceutical and academic researchers to assemble focused molecular cohorts without purchasing large quantities of unsuitable tissue.
General Questions
Frequent Asked Questions!!
FFPE blocks for genomics are formalin-fixed, paraffin-embedded tissue samples used for DNA, RNA, and biomarker analysis. They are widely used in cancer genomics, molecular pathology, translational research, and retrospective studies.
FFPE tissue blocks are valuable because they preserve tissue architecture and molecular material for long-term storage. Researchers can use them for sequencing, mutation analysis, biomarker discovery, and validation studies.
Yes. DNA can be extracted from FFPE blocks using validated extraction kits and optimized laboratory protocols. DNA quality depends on fixation time, block age, tissue type, tumor content, and storage conditions.
Yes. RNA can be extracted from FFPE tissue, although it is often fragmented because of formalin fixation. Specialized FFPE RNA extraction methods can provide material suitable for targeted RNA sequencing, gene expression studies, and fusion analysis.
Yes. High-quality FFPE blocks are commonly used for next-generation sequencing, including targeted sequencing panels, whole-exome sequencing, RNA sequencing, and selected whole-genome applications.
Tumor content requirements depend on the study design and testing method. Many molecular and NGS studies require at least 20% tumor content, while some projects may require 30%, 50%, or higher tumor percentage. Pathologist review can be performed to confirm tumor content before shipment
FFPE blocks can support mutation testing, copy number analysis, gene fusion detection, microsatellite instability testing, tumor mutational burden analysis, methylation studies, and targeted DNA or RNA sequencing.
Yes. FFPE cancer tissue blocks are extensively used to study genomic alterations in lung, breast, colorectal, prostate, ovarian, pancreatic, liver, kidney, and other tumor types.
Researchers can purchase FFPE blocks from qualified biospecimen suppliers, biobanks, pathology laboratories, hospitals, and research networks that provide ethically sourced and clinically annotated human tissue samples.
Researchers should confirm diagnosis, tissue type, tumor percentage, necrosis percentage, fixation details, block age, specimen size, available clinical data, pathology review, consent status, and intended research-use permissions.
Yes. Clinically annotated FFPE blocks may include donor age, sex, diagnosis, grade, stage, TNM classification, treatment history, pathology report, mutation status, and clinical outcome data.